Quoin Pharmaceuticals Lt-adr (QNRX) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

QNRX ranks #8522 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

QNRX is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

19 institutions disclose a position in QNRX, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 1.0% of its own portfolio to it.

UBS Group AG has added to its QNRX position for two straight quarters, increasing it by $32.5K to reach $32.8K today.

Ikarian Capital, LLC has trimmed its QNRX position for two straight quarters, cutting it by $2.0M while still holding $1.0M.

QNRX is up 4.7% today, and institutions have been net buyers of $3.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

QNRX reported a net loss of $15.8M in its latest fiscal year.

• Not yet profitable — net loss of $15.8M in the latest fiscal year
• Net income declined year over year, from -$9.0M to -$15.8M
• Operating cash flow was negative, using $13.5M in cash
• Current ratio of 3.61x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.55x equity — within a conventional range